BridgeBio Pharma Price to Free Cash Flow Ratio 2018-2026 | BBIO
Historical price to free cash flow ratio values for BridgeBio Pharma (BBIO) since 2018.
| BridgeBio Pharma Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-09-17 | 67.31 | 0.00 | |
| 2026-06-30 | 74.48 | $-2.23 | 0.00 |
| 2026-03-31 | 74.26 | $-2.30 | 0.00 |
| 2025-12-31 | 76.49 | $-2.33 | 0.00 |
| 2025-09-30 | 51.94 | $-3.11 | 0.00 |
| 2025-06-30 | 43.18 | $-3.50 | 0.00 |
| 2025-03-31 | 34.57 | $-2.62 | 0.00 |
| 2024-12-31 | 27.44 | $-2.80 | 0.00 |
| 2024-09-30 | 25.46 | $-2.51 | 0.00 |
| 2024-06-30 | 25.33 | $-2.42 | 0.00 |
| 2024-03-31 | 30.92 | $-3.54 | 0.00 |
| 2023-12-31 | 40.37 | $-3.25 | 0.00 |
| 2023-09-30 | 26.37 | $-3.12 | 0.00 |
| 2023-06-30 | 17.20 | $-3.16 | 0.00 |
| 2023-03-31 | 16.58 | $-2.72 | 0.00 |
| 2022-12-31 | 7.62 | $-2.88 | 0.00 |
| 2022-09-30 | 9.94 | $-3.22 | 0.00 |
| 2022-06-30 | 9.08 | $-3.18 | 0.00 |
| 2022-03-31 | 10.15 | $-3.55 | 0.00 |
| 2021-12-31 | 16.68 | $-3.54 | 0.00 |
| 2021-09-30 | 46.87 | $-3.39 | 0.00 |
| 2021-06-30 | 60.96 | $-3.62 | 0.00 |
| 2021-03-31 | 61.60 | $-3.80 | 0.00 |
| 2020-12-31 | 71.11 | $-3.45 | 0.00 |
| 2020-09-30 | 37.52 | $-3.53 | 0.00 |
| 2020-06-30 | 32.61 | $-2.57 | 0.00 |
| 2020-03-31 | 29.00 | $-3.19 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |